Introduction
TGF-b, a member of the TGF-b superfamily, elicits a wide range of biological responses (Kingsley, 1994; Massague, 1996; Roberts and Sporn, 1993) . To date, eight members of the Smad gene family have been identi®ed as molecules regulating TGF-b signaling from the membrane bound receptors to the nucleus. They can be classi®ed as receptor-activated Smads (Smad1, Smad5 and Smad8 for bone morphogenetic protein, Smad2 and Smad3 for TGF-b and activin), a shared Smad (Smad4) and inhibitory Smads (Smad6 and Smad7) Derynck et al., 1996; Eppert et al., 1996; Gra et al., 1996; Hahn et al., 1996; Hayashi et al., 1997; Hoodless et al., 1996; Lechleider et al., 1996; Liu et al., 1996; Riggins et al., 1996; Thomsen, 1996; Topper et al., 1997; Yingling et al., 1996; Zhang et al., 1996) . The Smad proteins share certain structural similarities in the conserved amino and carboxyl-terminal regions known as mad homology (MH) domains 1 and 2, respectively. MH2 has been shown to function in transcriptional activation and homo-and hetero-oligomer formation, while MH1, which binds to MH2, is thought to be a negative regulatory domain (Lagna et al., 1996; Hata et al., 1997; Shi et al., 1997) .
While TGF-b can elicit a growth inhibitory response in normal epithelial cells of various organs including the lung (Masuda et al., 1997; Masui et al., 1986) , unresponsiveness to TGF-b is commonly seen in human cancers (Roberts and Sporn, 1993) , lending support to the notion that defects in the TGF-b signaling pathway may be involved in carcinogenesis. Indeed, Smad4 was ®rst identi®ed as a tumor suppressor gene frequently altered in pancreatic cancers . We previously reported that Smad2 and Smad4 are also somatically mutated in a fraction of human lung cancers Uchida et al., 1996) . The vast majority of the Smad2 and Smad4 mutations in human cancers have been shown to aect residues in the conserved MH domains, especially MH2, and are presumed to disrupt TGF-b signal transduction (Eppert et al., 1996; Hahn et al., 1996; Le Dai et al., 1998; Nagatake et al., 1996; Riggins et al., 1997; Schutte et al., 1996; Uchida et al., 1996) . However, very few studies on such cancer-related mutations have been conducted with the aim of analysing their biological and biochemical involvement in the inactivation of TGFb signaling (Le Dai et al., 1998) . In addition, mutations that we have identi®ed in lung cancers do not exactly correspond to those related to developmental defects in other organisms such as C. elegance Sekelsky et al., 1995) . We therefore initiated the present study to characterize six such mutations naturally occurring in lung cancers. It could be clearly shown that they are indeed defective in mediating TGF-b-induced growth inhibition. Interestingly, they exhibited signi®cantly dierent patterns of impairment in the transcriptional activation and oligomer formation, suggesting complexity of inactivation mechanisms.
Results

DNA construct and protein levels of wild-type and mutant Smad
Our study examined two Smad2 mutants and four Smad4 mutants, which had been identi®ed in human lung cancers. These mutants comprised a substitution of histidine for asparagine (D450H) at codon 450 at the a-helix 5 (H5) and a 9-bp in-frame deletion (del1434-6) at codons 434 ± 436 at the loop 3 (L3) in the Smad2 gene, as well as a substitution of histidine for arginine (R420H) at codon 420 at the H2 helix, a substitution of proline for arginine (R441P) at codon 441 at the H3 helix and two frameshift mutations (203fs and 511fs), the former occurring at codon 203 at the linker region and the latter at codon 511 at the L3 loop ( Figure 1a ). Transient transfection into COS cells con®rmed that the expression levels of these Smad2 and Smad4 mutants were similar to those of wild-type Smad2 and Smad4 (Figure 1b) .
Impairment of TGF-b induced growth inhibition
We ®rst examined whether Smad mutants identi®ed in lung cancers had lost their ability to transmit the growth inhibitory signals concerned in normal lung epithelial cells (Figure 2 ). Expression constructs of Smads were introduced into a human normal lung epithelial cell line, BEAS2B, together with a plasmid carrying hygromycin resistance gene, followed by selection with 100 mg/ml of hygromycin for 2 weeks in the absence or presence of 1 ng/ml of TGF-b. The similarity of protein expression levels of wild-type and mutant Smad2 and Smad4 in BEAS2B cells was con®rmed by Western blot analysis (Figure 2 Impairment of TGF-b-induced transcriptional activation in cooperation with hFAST-1 A recently cloned human homolog of the Xenopus forkhead activin signal transducer-1 (hFAST-1) interacts with Smad hetero-oligomers and transmits TGF-bmediated signals through cooperative binding to FBE and SBE (Zhou et al., 1998) . Using a FBE/SBE-lux reporter construct and a hFAST-1 expression construct, we examined the ability of Smad mutants to induce Smad/hFAST-1-mediated transactivation in mink lung epithelial cell line, MvLu1 (Figure 3a) . Cotransfection of wild-type Smad2 and Smad4 exhibited signi®cant transcriptional activation in response to TGF-b. In contrast, all of the Smad2 and Smad4 mutants showed markedly impaired ability to activate the Smad/hFAST-1-mediated transcription when cotransfected with their respective wild-type Smad counterparts.
We further examined whether these Smad mutants have a dominant negative eect on the wild-type Smads in the Smad/hFAST-1-mediated transcriptional activation ( Figure 3b ). Each mutant Smad construct was cotransfected into MvLu1 cells together with both wild-type constructs of Smad2 and Smad4, resulting in the clear inhibition of the TGF-b-induced, Smad/ hFAST-1-mediated transcriptional activation. Furthermore, cotransfection experiments using various amounts (0.1, 0.5 and 1.0 mg) of mutant Smad constructs together with 1.0 mg each of wild-type Smad2 and Smad4 clearly showed dose-dependent inhibition of the Smad/hFAST-1-mediated transcriptional activation (Figure 3c ). These results imply that these mutants inhibit Smad/hFAST-1-mediated TGF-b signaling in a dominant negative fashion.
Impairment of TGF-b-induced transcriptional activation of the PAI-1 promoter
We also examined transcriptional activating function of the Smad mutants using a PAI-1-luciferase reporter construct ( Figure 4a ). Cotransfection of wild-type Smad2 and Smad4 exhibited signi®cant transcriptional activation in the PAI-1 promoter in response to TGFb. In contrast, none of the Smad2 and Smad4 mutants could fully transactivate the PAI-1 promoter when cotransfected with their respective wild-type Smad counterparts. One Smad2 mutant (D450H) and three Smad4 mutants (203fs, R420H and 511fs) exhibited severe impairment of PAI-1 transactivation, whereas one each of Smad2 (del434-6) and Smad4 (R441P) mutants appeared to partially retain their activity.
We further examined whether these Smad mutants have a dominant negative eect over the wild-type Smads in the transcriptional activation of the PAI-1 promoter (Figure 4b ). Each mutant Smad construct was cotransfected together with the wild-type Smad2 and Smad4 expression constructs into BEAS2B cells. Cotransfection of D450H, 203fs, R420H and 511fs clearly inhibited transcriptional activation of the PAI-1 promoter mediated by the combination of wild-type Smad2 and Smad4. In contrast, cotransfection of del434-6 and R441P did not result in such dominant negative inhibition of the PAI-1 promoter activation.
Homomeric and heteromeric oligomerization of mutant Smad2 and Smad4
The capabilities of homo-and hetero-oligomerization of mutant Smads with wild-type Smads were also examined ( Figures 5 and 6) . Each of the mutant Smad constructs, which were tagged with either Flag, myc or HA, were cotransfected into COS cells with their respective partners of wild-type Smads. Five of the six Smad mutants, del434-6 Smad2 mutant and 203fs, R420H, R441P and 511fs Smad4 mutants, showed themselves capable of homo-oligomerization with wildtype Smad (data not shown for 203fs). The only exception was the D450H mutation of Smad2, which completely disrupted homo-oligomerization with wildtype Smad2. As to hetero-oligomerization, four of the six Smad mutants, the D450H Smad2 mutant and 203fs, R420H and 501fs Smad4 mutants, had lost their ability to form a hetero-oligomer with their respective wild-type Smad counterparts (data not shown for 203fs). It is worth noting that the del434-6 Smad2 mutant and the R441P Smad4 mutant showed no defects in homo-and hetero-oligomerization.
Discussion
Our study has demonstrated that all of the Smad2 and Smad4 mutants identi®ed in human lung cancers are indeed defective in their capabilities of transmitting TGF-b-induced growth inhibitory signals. This ®nding indicates the functional signi®cance of these mutants in the development of lung cancers. It is interesting that considerable dierences were observed in the impairment of the transactivation function of the Smad mutants. All of the Smad2 and Smad4 mutants uniformly failed to activate Smad/hFAST-1-mediated transcription in a dominant negative manner, whereas PAI-1 transactivation was shown to be impaired in various degrees. For example, the del434-6 Smad2 and R441P Smad4 mutants exhibited rather modest reduction in the PAI-1 promoter activation and did not show any dominant negative inhibition of PAI-1.
It has been clearly shown that hetero-oligomer formation between Smad2 and Smad4 is required for the transduction of TGF-b-induced signals into the nucleus (Lagna et al., 1996; Hata et al., 1997; Shi et al., 1997) . Previous structural analyses of the Smad protein revealed that Smads form homo-and hetero-oligomers at the MH2 carboxy-terminal domain and directly bind to the DNA binding sequence of the TGF-b responsive genes with the amino-terminal domain of Smads (Shi et al., 1997 (Shi et al., , 1998 . It has also been shown that H5 of Smad4 forms an interface for homo-oligomerization, while L3 of Smad4 is involved in hetero-oligomerization. However, the functions of H5 of Smad2 as well as of H2 and H3 of Smad4 have not been clari®ed yet.
In the present study, we have shown that the six Smad mutants identi®ed in lung cancers can be classi®ed into three groups according to their capability to form oligomers. The ®rst group includes three Smad4 mutants, 203fs, R420H and 511fs, which can form homo-oligomers with wild-type Smads but have lost their hetero-oligomer forming capability with their respective partners. Our ®nding of a defect in the hetero-oligomerization of R420H suggests that H2 of Smad4 might be involved. Moreover, we showed that all of these mutants exhibit dominant negative inhibition in the transcriptional activation of the PAI-1 promoter as well as in the Smad/hFAST-1-mediated transcriptional activation. It is conceivable that these three mutants may sequester wild-type Smad4 into an inactive homo-oligomer, which is incapable of heterooligomer formation. Our results with 203fs are similar to those of a previous report on the dominant negative inactivation of an arti®cial truncation mutant lacking MH2, which was shown to be capable of forming only a homo-oligomer (Hata et al., 1997) . The second type is the D450H Smad2 mutant. A previous report showed that an arti®cial D537E Smad4 mutant at the H5 helix (corresponding to D450E Smad2 mutant naturally occurring in colon cancer) had become incapable of homo-oligomerization with itself (Shi et al., 1997) . Our ®nding shows that D450H mutation of Smad2 also leads to a defect in the formation of homo-and hetero-oligomers with wildtype Smads, although it is surmised that there may be some dierences between D450H and D450E because of dierence in the charge of the substituted amino acids. Taken together, these observations suggest that H5 of Smad2 may play a role in homo-oligomerization. Nevertheless, further studies are required for a de®nitive explanation of how this mutant exhibits a dominant negative eect on PAI-1 promoter activation and Smad/hFAST-1-mediated transcription, one possible explanation is that this mutant may occupy TGFbRI or sequester a cofactor, which is required for transcriptional activation in cooperation with wild-type Smad2 and Smad4. The remaining group, del434-6 and R441P, has apparently retained its capabilities to form both homomeric and heteromeric oligomers. We also con®rmed nuclear accumulation of del434-6 Smad2 and R441P Smad4 mutant proteins as well as of wildtype Smad2 and Smad4 in response to TGF-b in BEAS2B (data not shown). These results are consistent with the ®nding of only modest impairment in the PAI-1 promoter activation. Therefore, signi®cant loss of growth inhibitory activity and Smad/hFAST-1-mediated transcriptional activation must be attributable to a defect(s) in other aspects, such as impaired interaction with other transcription factors, since accumulating evidence suggests that Smad heterooligomers interact with various other transcriptional factors such as AP1, Sp1 and p300 (Yingling et al., 1997; Shen et al., 1998; Moustakas and Kardassis, 1998) , depending on the promoters involved. Further studies using del434-6 and R441P mutants should help gain a better understanding of the molecular mechanism involved in the TGF-b-induced growth inhibition of lung epithelial cells.
Our study has shown that loss of growth inhibition and impairment of the Smad/hFAST-1-mediated transactivation are consistent features of Smad2 and Smad4 alterations acquired during lung tumorigenesis, in contrast to a variety of degrees of impairment of the homo-and hetero-oligomer formation as well as of the PAI-1 promoter activation. The thorough characterization of Smad mutants presented here should prove a valuable resource for gaining an insight into how TGFb-mediated signals contribute to the regulation of lung epithelial cell growth and how disturbances of the TGF-b signaling pathway lead to cell transformation. Further understanding of the mechanisms of their functional defects may ultimately enable us to identify novel ways to restore the TGF-b mediated growth suppressive signals.
Materials and methods
DNA construct
Wild-type and mutant Smad2 and Smad4 cDNAs were generated using the following oligonucleotide primers: Smad2S (sense), 5'-AGCTCTAGATGGCTTGCTGCCTTT-GGTAAG; Smad2AS (antisense), 5'-AGCGAATTCAAGT-CTTTTCCATGGGACTTG; Smad4S (sense), 5'-AGCAAG-CTTGCTTCAGAAATTGGAGAC; Smad4AS (antisense), 5'-AGCGGATCCCCATCCTGATAAGGTTAAGGGC.
Expression vectors of Smad2 and Smad4 with N-terminal Flag-tag were constructed by cloning of their cDNAs into the EcoRI site of pFlag-CMV2 (Sigma Chemical Co., St. Louis, MO, USA). pcDNA3-myc and pcDNA3-HA were prepared by inserting an annealed oligonucleotide encoding epitope-tag sequence between the KpnI and EcoRI and between EcoRI and EcoRV sites of pcDNA3 (Invitrogen Co., Carlsbad, CA, USA), respectively. N-terminally myc-tagged wild-type Smad2 was constructed by cloning of its cDNA into the EcoRI site of pcDNA3-myc. N-terminally HA-tagged wildtype and mutant Smad4 were constructed by cloning of their cDNAs into the S®I site of pcDNA3-HA. All the polymerase chain reaction products were sequenced thoroughly.
Western blot analysis
Cells transfected with Smad expression constructs were washed, scraped and solubilized in the SDS sample buer containing 0.7 mM b-mercaptoethanol and subjected to SDS ± PAGE. Proteins were electrotransferred to Immobilon-P membranes (Millipore Co., Bedford, MA, USA). We used the anti-Flag M2 antibody (Eastman Kodak Co., Rochester, NY, USA) for the Flag-tagged construct, the anti-myc 9E10 monoclonal antibody (Berkeley Antibody Co., Richmond, CA, USA) for the myc-tagged construct and the anti-HA Y-11 antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) for the HA-tagged construct. The ECL kit (Amersham Life Science, Buckinghamshire, UK) was used for visualization.
Cell culture and assay for antiproliferative effect
A normal human bronchial epithelial cell line, BEAS2B (Reddel et al., 1988) , was maintained as previously described. BEAS2B cells (1610 6 ) were transfected with 15 mg of various sets of plasmid DNAs together with pTA-hyg, which contains hygromycin resistant gene, using 40 ml of DMRIE-C according to the manufacturer's instructions (Life Technologies, Inc., Gaithersburg, MD, USA). Five hours after transfection, cells were refed with fresh medium. Transfected cells were split on the following day and selected with 100 mg/ ml of hygromycin (GIBCO, Bethesda, MD, USA) 
FBE/SBE luciferase reporter assay
Various combinations of expression plasmids for wild-type and mutant Smads were cotransfected with wild-type hFAST-1 and a luciferase reporter plasmid FBE/SBE-lux (Zhou et al., 1998) , which contains the hFAST-1 binding element (FBE), the Smad binding element (SBE) and the luciferase reporter gene. pCMVbgal, which expresses b-galactosidase under the control of the cytomegalovirus promoter, was included in all transfections to allow normalization of the luciferase activity for transfection eciency. 3610 5 cells of MvLu1 were transfected with the aid of DMRIE-C. In each experiment, 1.0 mg each of the expression plasmids was transfected as indicated together with 0.3 mg of FBE/SBE-lux and 0.3 mg of pCMVbgal. Five hours after transfection, cells were split and cultured in the presence or absence of 1 ng/ml TGF-b. After 48 h, the cells were lysed and luciferase assays were performed according to the standard procedure. At least three independent transfections were done in triplicate each using dierent plasmid preparation. Values represent luciferase activity relative to that of wild-type transfectant incubated in the absence of TGF-b and are shown as mean+s.d. of a representative experiment.
PAI-1 luciferase reporter assay
Expression plasmids for wild-type and mutant Smads were cotransfected with a luciferase reporter plasmid p800-luc , which contains elements from the TGFb responsive PAI-1 promoter. pCMVbgal was included in all transfections for normalization of transfection eciency. BEAS2B cells ( 3610 5 ) were transfected with the aid of DMRIE-C. In each transfection, 1.2 mg each of expression plasmids were used together with 0.5 mg of p800-luc and 0.5 mg of pCMVbgal. Five hours after transfection, cells were split and cultured in the presence or absence of 1 ng/ml TGFb. After 48 h, the cells were lysed and luciferase assays were performed. At least three independent transfections were done in triplicate each using dierent plasmid preparation. Values represent luciferase activity relative to that of wildtype transfectant incubated in the absence of TGF-b and are shown as mean+s.d. of a representative experiment.
Immunoprecipitation and immunoblotting
COS cells were maintained in Dulbecco's modi®ed Eagle's medium containing 5% fetal calf serum. 3610 5 cells of COS were transfected with expression plasmids of Smads in combination with either wild-type TGF-b receptor type I (TGF-bRI) or a constitutively activated form of TGF-bRI (TD) . Following 5 h incubation, cells were refed with fresh medium. Seven mM lactacystin was included in the medium of 511fs Smad4 mutant transfectants. Twenty-four hours after transfection, cells were washed, scraped and solubilized in a buer containing 10 mM HEPES pH 7.5, 300 mM NaCl, 5 mM EDTA, 0.5 mM dithiothreitol, 1 mM Na 3 VO 4 , 300 mM NaF, 2 mM phenylmethylsulfonyl uoride and 0.5% NP-40. After incubation for 10 min at 48C with rocking, the cell lysates were pelleted by centrifugation and the supernatants were incubated with anti-Flag M2 for 2 h, followed by incubation with protein G-Sepharose beads (Amersham Life Science, Buckinghamshire, UK) for 1 h at 48C. The beads were washed four times with the buer used for cell solubilization. The immune complexes were then eluted by boiling for 3 min in the SDS sample buer containing 0.7 mM b-mercaptoethanol and subjected to SDS ± PAGE. Proteins were electrotransferred to Immobilon-P membranes. The anti-myc 9E10 monoclonal antibody was used for the investigation of homo-oligomerization of Smad2, while anti-HA Y-11 antibody were employed for the investigation of homo-oligomerization of Smad4 as well as of hetero-oligomerization between Smad2 and Smad4. The ECL kit was used for visualization.
